中医药调控PD-1/PD-L1通路干预恶性肿瘤研究进展  

Research Progress in TCM Regulating PD-1/PD-L1 Pathway in Malignant Tumors

作　　者：巨欢 赵丹 李丹 陈如熙 韩彬[1] JU Huan;ZHAO Dan;LI Dan;CHEN Ruxi;HAN Bin(Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China;The Hospital of Traditional Chinese Medicine in Chengdu’s Pidu District,Chengdu 610000,China;Beijing Daxing District People’s Hospital,Beijing 102600,China;Hunan University of Chinese Medicine,Changsha 410208,China)

机构地区：[1]川北医学院附属医院,四川南充637000 [2]成都市郫都区中医医院,四川成都610000 [3]北京市大兴区人民医院,北京102600 [4]湖南中医药大学,湖南长沙410208

出　　处：《中国中医药信息杂志》2024年第8期187-192,共6页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：国家自然科学基金青年科学基金(81903660);四川省科技计划应用基础研究项目(2019YJ0386)。

摘　　要：程序性死亡受体1/程序性死亡配体1(PD-1/PD-L1)通路是逃脱机体免疫监视与杀伤、发生免疫逃逸的重要途径,在多种肿瘤中广泛表达。通过调控PD-1/PD-L1信号通路表达,能重新激活抗肿瘤免疫应答,阻止肿瘤细胞发生免疫逃逸。PD-1/PD-L1抑制剂在肿瘤的治疗过程中发挥重要潜力,但存在一定局限性。中医药能调节机体免疫力、改善肿瘤微环境、延长生存期。本文基于中医药在调控PD-1/PD-L1表达、联合PD-1/PD-L1抑制剂在抗肿瘤方面的应用,对现有研究进行梳理,为中医药与免疫检查点抑制剂联合应用抗肿瘤提供参考。Programmed death receptor programmed death ligand 1(PD-1/PD-L1)pathway is an important way to escape from immune surveillance and killing and producing immune escape and is widely expressed in various tumors.By regulating the expression of PD-1/PD-L1 signaling pathway,it can reactivate the anti-tumor immune response and prevent tumor cells from immune escape.PD-1/PD-L1 inhibitors play an important potential in the treatment of tumors,but it has certain limitations.TCM can regulate the body’s immune system,improve the tumor microenvironment,and prolong survival.Based on the TCM regulation of PD-1/PD-L1 expression and the application of combining with PD-1/PD-L1 inhibitors in anti-tumor therapy,this study summarized the existing research content and provides reference for the combined application of TCM and immune checkpoint inhibitors in anti-tumor therapy.

关 键 词：中医药 免疫治疗 PD-1/PD-L1免疫抑制剂 肿瘤免疫 作用机制 综述 

分 类 号：R273[医药卫生—中西医结合]